Peptide Knowledge Base · Cognition
Semax: what it is, what the evidence says, and its real status
A nootropic peptide studied for focus and mental clarity.
Short version: a Russian nootropic peptide for focus and clarity. Interesting clinical history, thin Western evidence, under FDA review, waitlist and education only.
Can you actually get it?
Plain-English verdict: Waitlist.
Regulatory status: Under PCAC review · PCAC · Jul 23–24, 2026.
Not available to prescribe today. On the PCAC agenda; the Western evidence is thin, so it lives here as education and waitlist.
How does Semax work?
A synthetic ACTH fragment proposed to influence BDNF and attention-related signaling.
What it does — and what it does not do
What it does: Researched for focus, attention, and stress-resilience support.
What it does not do: It is not a treatment for any cognitive or psychiatric condition, and we don't offer it today.
How honest is the evidence?
Evidence grade C — limited or mixed human data. Read our grading methodology for what each grade means.
What we still don't know: Western trial evidence is minimal; long-term effects are uncharacterized.
WADA status: Not prohibited.
How it is taken
No established Western clinical dosing; research-stage.
Who should not take it
Not characterized in Western practice; not a substitute for care of any cognitive or mood condition.
Sources
Russian clinical literature on Semax (limited Western replication) · FDA PCAC docket, Jul 2026
Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker or the knowledge base.
Last reviewed 2026-08-11 · Peptós.LIFE · Not medical advice.